- Home
- MESO vs OBX Comparison
MESO vs OBX Comparison
Compare MESO & OBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MESO | OBX |
|---|---|---|
| Founded | 2004 | N/A |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.7B |
| IPO Year | 2005 | 2026 |
Fundamental Metrics
Financial Performance| Metric | MESO | OBX |
|---|---|---|
| Price | $16.97 | $17.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 180.0K | 59.9K |
| Earning Date | 02-26-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $629.74 | N/A |
| Revenue Next Year | $30.65 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.66 | $14.57 |
| 52 Week High | $21.50 | $39.00 |
Technical Indicators
Market Signals| Indicator | MESO | OBX |
|---|---|---|
| Relative Strength Index (RSI) | 61.29 | 30.30 |
| Support Level | $13.66 | N/A |
| Resistance Level | $18.09 | $39.00 |
| Average True Range (ATR) | 0.35 | 6.38 |
| MACD | 0.15 | -1.23 |
| Stochastic Oscillator | 93.10 | 13.02 |
Price Performance
Historical ComparisonAbout MESO Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.